LENZ · LENZ Therapeutics, Inc. · Metrics
Market Cap
$140.45M
Shares
31.42M
LENZ metrics
62 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$4.13
Market cap
$140.45M
Price action
20 metricsPrice change (1W)
-15.7%
Price change (30D)
-13.2%
Price change (3M)
-34.7%
Price change (6M)
-64.7%
Price change (YTD)
-74.1%
Price change (1Y)
-90.0%
Trailing year
Price change (5Y)
—
52-week high
$49.05
52-week low
$4.14
Change from 52-week high
-91.6%
Change from 52-week low
+0.0%
Annualized volatility
81.4%
Annualized volatility (3M)
69.1%
Beta
1.5
RSI (14D)
33.5
Price vs SMA 50
-19.2%
Price vs SMA 200
-61.1%
Avg volume (3M)
891,100
Relative volume
0.9
Average dollar volume
$4.71M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
31.42M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
6.5×
reciprocal yield 15.3%
P / book
0.6
reciprocal yield 156.1%
FCF yield
-81.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-89.7%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-11
Profitability
9 metricsGross margin
97.8%
Operating margin
-631.7%
Trailing 12 months
Net margin
-586.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$135.66M
Net income (TTM)
−$126.00M
Trailing 12 months
Diluted EPS (TTM)
$-4.13
FCF margin
-532.8%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+9.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$21.48M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+11.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-57.5%
Return on assets
-53.3%
Debt / equity
—
Current ratio
13.6
EBITDA (TTM)
−$135.20M
Free cash flow (TTM)
−$114.42M
Quick ratio
13.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$24.21M
Latest balance sheet
Cash & equivalents
$24.21M
Total assets
$236.60M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$113.91M
Capital expenditures (TTM)
$511,000
R&D (TTM)
$3.79M
SG&A (TTM)
$151.57M
Stock compensation (TTM)
$15.94M
R&D / revenue
17.7%
Stock compensation / revenue
74.2%
Ownership (13F)
3 metrics13F filers
147
13F filer change QoQ
-1
Institutional ownership
111.6%
Short interest
3 metricsShort interest
34.6%
Latest settlement · 18.9 days to cover
Days to cover
18.9d
Short-squeeze score
67 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—